Gayatri BioOrganics logo

Gayatri BioOrganics financials: balance sheet, profit and loss, cash flow

BSE: 524564Chemicals & PetrochemicalsSmall Cap

Gayatri BioOrganics Ltd · Face value ₹10 · Listed Jul 1994
Last close ₹8.00₹0.00 (0.00%)

Share price at the BSE close on 27 Oct 2026. Previous close ₹8.00.

27 Oct: open ₹8.40, high ₹8.40, low ₹8.00

52-week range of traded prices to 27 Oct 2026
₹6.25Low, 23 Jul 2026₹20.25High, 6 May 2026
Market cap
₹63 Cr2,858th largest listed
P/E
Lossover the last 12 months
P/B
Net worth zero or below
Dividend yield
Nonein the last 12 months
ROE
Net worth zero or below
Debt to equity
Net worth zero or below
Volume, BSE
2,210

Gayatri BioOrganics' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Gayatri BioOrganics annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
−83Mar 17−19Mar 180−1635Mar 1908435Mar 200−0.535Mar 210−0.535Mar 221.7−1.036Mar 230−0.736Mar 240−0.737Mar 250−1.137Mar 26
A loss in 9 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
−46.1%−60.6%−46.1%−60.6%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

The years either side of a change of basis do not compare. From the year to Mar 2019, the company reports a discontinued business.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue0.0
  2. Employee costs−0.1
  3. Other expenses−0.6
  4. Operating profit−0.8
  5. Depreciation0.0
  6. Other income0.0
  7. One-off items0.0
  8. Finance costs−0.4
  9. Profit before tax−1.1
  10. Tax0.0
  11. Net profit−1.1

What the company owns

  • Plant, investments and other assets₹1 Cr
  • Receivables₹0 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Borrowings₹37 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Gayatri BioOrganics quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 MayJun 2026Twelve monthsFiled 4 Aug
Revenue from operations––0.00.00.00.01.70.00.00.02.3
––0.00.60.50.52.40.50.40.82.9
Materials and goods bought––0.00.00.00.01.60.00.00.02.2
Employee costs––0.00.30.30.30.10.10.10.10.1
Other expenses––0.00.30.20.20.70.40.40.60.7
Operating profit before depreciation––0.0−0.6−0.5−0.5−0.8−0.5−0.4−0.8−0.6
Operating margin––––––−46.1%––––
Materials, % of revenue––––––95.2%––––
Employee costs, % of revenue––––––8.2%––––
Other expenses, % of revenue––––––42.7%––––
Depreciation and amortisation––0.00.00.00.00.00.00.00.00.0
Operating profit after depreciation––0.0−0.6−0.5−0.5−0.8−0.5−0.4−0.8−0.6
Other income––0.00.10.00.00.00.00.00.00.0
Finance costs––0.00.00.00.00.00.10.30.40.4
One-off items––0.00.00.00.00.00.00.00.00.0
Profit before tax––0.0−0.6−0.5−0.5−0.8−0.7−0.7−1.1−1.0
Tax––0.00.00.00.00.20.00.00.00.0
Profit from discontinued businesses––−15.585.0–––––––
Net profit−82.6−19.1−15.584.5−0.5−0.5−1.0−0.7−0.7−1.1−1.0
Other comprehensive income––1.00.00.00.00.00.00.00.00.0
Total comprehensive income––−14.584.5−0.5−0.5−1.0−0.7−0.7−1.1−1.0
Net margin––––––−60.6%––––

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
−117−32−33−33−34−35−36−37
Share capital7979797979797979
Reserves−196−111−112−112−113−114−115−116
3535353536363737
343434343434343
Liabilities due after a year222223335
Liabilities going with businesses held for sale227–––––––
1453322222
00000000
23321222
Net debt3534353536363737
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
−0.52−0.40−0.56−0.69−0.55−0.08
−0.52−0.40−0.35−0.69−0.55−0.08
−0.020.090.42−0.16−0.100.68
Receivables0.000.000.230.000.000.00
Payables0.000.03−0.19−0.040.03−0.04
Other working capital−0.020.060.38−0.13−0.130.71
Tax paid0.000.00−0.210.000.000.00
Capital spending0.000.000.000.000.000.00
Free cash flow−0.52−0.40−0.56−0.69−0.55−0.08
Cash from investing0.000.000.000.000.000.00
0.000.000.560.700.540.74
Dividends paid0.000.000.000.000.000.00
Shares bought back0.000.000.000.000.000.00
Shares issued0.000.000.000.000.000.00
Net change in cash−0.52−0.40−0.010.01−0.010.66
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
Earnings per share−₹10.49––₹10.72−₹0.06−₹0.06−₹0.13−₹0.09−₹0.09−₹0.14
Diluted earnings per share−₹10.49––₹10.72−₹0.06−₹0.06−₹0.13−₹0.09−₹0.09−₹0.14
Book value per share––−₹14.84−₹4.12−₹4.19−₹4.25−₹4.38−₹4.46−₹4.56−₹4.70
Shareholder yield––––0.0%0.0%0.0%0.0%0.0%0.0%
Market cap at the year end (₹ crore)13052171051148563954109
Earnings per share is left blank for the years to Mar 2018 and Mar 2019: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Standalone, years to March.Gayatri BioOrganics PE ratio and valuation

RatioMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 19 May
Revenue growth––––−100.0%––
Return on equity–––3.0%–––
Return on capital employed−23.2%−23.3%−30.4%−65.4%−44.5%−44.6%–
Receivable days–––0–––
Inventory days–––0–––
Payable days–––49–––
Cash conversion cycle, days–––−49–––
Working capital days–––196–––
Asset turnover–0.000.000.870.000.000.00
Assets per rupee of net worth–−0.09−0.07−0.06−0.05−0.05−0.05
Return on equity, asset turnover and assets per rupee of net worth are left blank for the years to Mar 2019 and Mar 2020: a tenth or more of the assets on the balance sheet it is worked from are held for sale or for a demerger, so it would mix the business being kept with the part that is leaving. Change in return on equity, from the net margin, from asset turnover and from borrowing are left blank for the years to Mar 2019, Mar 2020 and Mar 2021: a tenth or more of the assets on the balance sheet it is worked from are held for sale or for a demerger, so it would mix the business being kept with the part that is leaving. Debt to equity, receivable days, inventory days, payable days, cash conversion cycle, days, return on capital employed and working capital days are left blank for the year to Mar 2019: a tenth or more of the assets on the balance sheet it is worked from are held for sale or for a demerger, so it would mix the business being kept with the part that is leaving. Interest cover is left blank for the years to Mar 2020, Mar 2021, Mar 2022, Mar 2023, Mar 2024, Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. Debt to equity is left blank for the years to Mar 2020, Mar 2021, Mar 2022, Mar 2023, Mar 2024, Mar 2025 and Mar 2026: net worth is below zero, so there is no shareholders' money to set the borrowings against. Return on capital employed is left blank for the year to Mar 2026: net worth and borrowings together come to nought or less, so there is no money employed to set the operating profit against. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−65.8%
Measure5 years3 years
Return on capital employed, average−46.2%−44.6%
Asset turnover, average0.170.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−2.29−1.32−0.08
Cash from investing0.000.000.00
Cash from financing2.531.980.74
Capital spending0.000.000.00
Dividends paid0.000.000.00
Shares bought back0.000.000.00
Shares issued for cash0.000.000.00
Borrowings raised1.981.980.74
Borrowings repaid0.560.000.00

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Altman Z-scorePublished threshold 1.81−2.11–−74.62−85.66−121.88−126.12−119.92−95.39
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––0.70−3.80−23.200.80−10.86−61.33
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––––−17.33–––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
4 May 2026CARE Ratings LimitedFund-based - LT-Term LoanLong-term scaleCARE D; ISSUER NOT COOPERATING*Review, Re-affirm1.66
4 May 2026CARE Ratings LimitedFund-based - LT-Cash CreditLong-term scaleCARE D; ISSUER NOT COOPERATING*Review, Re-affirm15
4 May 2026CARE Ratings LimitedNon-fund-based - ST-Letter of creditShort-term scaleCARE D; ISSUER NOT COOPERATING*Review, Re-affirm10
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.